An Open-Label Pilot Study of Losmapimod to Evaluate the Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments in Subjects With Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) with Extension
This research study is investigating a new medicine, Losmapimod, for individuals diagnosed with Facioscapulohumeral Muscular Dystrophy 1, often called FSHD1. It's an early-stage study, meaning it's one of the first times this specific medicine is being tested in people with FSHD1. The main goals are to carefully check if the medicine is safe and if people can take it without too many side effects. Researchers will also look for any changes in markers in the body and how people's symptoms are affected. This type of study helps us understand if a new treatment might be helpful for FSHD1 in the future, laying the groundwork for larger studies.
De un vistazo
¿De qué trata este estudio?
This study is a research project focusing on a condition called Facioscapulohumeral Muscular Dystrophy 1, or FSHD1. FSHD1 is a genetic condition that causes muscles to become weak, especially in the face, shoulders, and upper arms. There isn't a cure for FSHD1 yet, so scientists are always looking for new ways to manage the condition and improve the lives of people who have it.
In this study, researchers are testing a new medicine called Losmapimod. This is an "open-label" study, meaning both the patients and the doctors will know who is receiving the study medicine. It's also a "pilot study," which means it's a small, early-stage trial. The main purpose of this pilot study is to see if Losmapimod is safe for people with FSHD1 and how well their bodies tolerate it. They will closely watch for any side effects and how patients feel while taking the medicine.
Beyond safety, the study will also explore if Losmapimod makes any subtle changes in the body that can be measured (these are called biomarkers) and if it has any effect on how FSHD1 symptoms show up or progress. This initial information is really important because it helps doctors decide if Losmapimod should be studied in more detail in larger, longer trials in the future. It's a crucial step in the journey to finding new treatments.
Puntos clave
- This study is exploring a new medicine (Losmapimod) for FSHD1.
- It's an early-stage study focused on safety and tolerability.
- Participants must be 18 years or older, both men and women are welcome.
- Regular clinic visits for health checks and blood tests will be required.
- There's no guarantee the medicine will help, and side effects are possible.
- Joining is voluntary, and you can withdraw at any time.
¿Quién puede ser elegible?
To join this study, you need to be an adult, at least 18 years old. There isn't an upper age limit mentioned, so adults of any age might be considered.
The study is open to both men and women. The detailed rules about who can and cannot take part will be explained by the study team, but generally, they will look for people with a confirmed diagnosis of Facioscapulohumeral Muscular Dystrophy 1 (FSHD1).
Other things like your general health, any other medications you are taking, or any other medical conditions you have will also be carefully checked to make sure it's safe for you to participate in this specific study. It’s important that you discuss all your health information openly with the study doctors.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- ¿Tienes 18 años o más?
- Do you have a diagnosis of Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)?
- Are you able to attend regular clinic appointments?
- Are you willing to take a new experimental medicine?
- Are you comfortable with blood tests and other medical checks?
¿En qué consiste la participación?
If you decide to take part in this study, you would be taking a medicine called Losmapimod. The study doctors would give you clear instructions on how and when to take it. Throughout the study, you would need to attend several appointments at the study clinic. During these visits, the doctors and nurses would check on your health and gather information.
These checks would include things like taking blood and urine samples (for laboratory tests), performing electrocardiograms (ECGs, which check your heart's electrical activity), and measuring your vital signs like blood pressure and heart rate. They would also ask you questions about how you are feeling and any side effects you might be experiencing. The total length of your participation, including any follow-up visits after you stop taking the medicine, would be fully explained by the study team.
Riesgos y beneficios potenciales
Ubicaciones (1)
- —No verificadoPaíses Bajos
Preguntas comunes
What is Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)?
FSHD1 is a genetic condition that causes muscles to become weak, especially in the face, shoulders, and upper arms.
What is the new medicine being tested?
The medicine being tested is called Losmapimod.
What is a 'pilot study'?
A pilot study is a small, early-stage trial designed mainly to check if a new medicine is safe and well-tolerated in people.
Will I know if I'm getting the study medicine?
Yes, this is an 'open-label' study, meaning everyone involved, including participants, will know you are receiving Losmapimod.
Can I leave the study once I've joined?
Yes, you can choose to leave the study at any time, for any reason, without it affecting your normal medical care.
Cómo obtener más información
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.